Loading...
Please wait, while we are loading the content...
Similar Documents
Non-vitamin K antagonist oral anticoagulants (NOACs) for the management of venous thromboembolism.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Blann, Andrew D. Lip, Gregory Y. H. |
| Copyright Year | 2016 |
| Abstract | ### Learning objectives Thrombosis is the common pathophysiology responsible for ischaemic heart disease, ischaemic stroke and venous thromboembolism (VTE), and a major contributor to the global disease burden.1 This effect is markedly more pronounced by considering the view that cancer is also a thrombotic disease.2 ,3 Cardiovascular disease (CVD, manifesting as acute coronary syndromes, myocardial infarction and stroke) is almost entirely related to thrombosis within arteries. However, many of the risk factors for arterial thrombosis are also risk factors for VTE, and in addition VTEs have additional risk factors such as obesity and cancer.4 ,5 Indeed, VTE is a risk factor for subsequent arterial thrombosis.6 Some risk factors (such as orthopaedic surgery, certain types of valve disease and cardioversion for atrial fibrillation (AF)) are so strong, that anticoagulation is mandatory.7 VTE, manifesting principally as deep vein thrombosis (DVT) and pulmonary embolism (PE) is a frequent complication among hospital inpatients and contributes to longer hospital stays, morbidity and mortality. For example, without antithrombotic prophylaxis, DVT has been documented in over a third of all major orthopaedic operations. Although traditionally considered separate diseases, it is now accepted that DVT and PE are a single clinical entity: 50–80% of those presenting with DVT have evidence of PE while over 80% of those presenting with a PE have asymptomatic DVT. Clinical practice of the prevention and treatment of VTE is compounded by the fact that some risk factors (such as active malignancy) are more likely than others (such as diabetes) to evoke a VTE.5 ,8 Anticoagulation is considered in numerous diverse clinical situations. However, the variable medical … |
| File Format | PDF HTM / HTML |
| DOI | 10.1136/heartjnl-2014-307019 |
| PubMed reference number | 26984888 |
| Journal | Medline |
| Volume Number | 102 |
| Issue Number | 12 |
| Alternate Webpage(s) | http://www.suc.org.uy/emcc2016/AnticoagulantesCardiologia-20116_archivos/Non-vitamin%20K%20antagonist%20oral%20anticoagulants%20(NOACs)%20for%20the%20management%20of%20venous%20thromboembolism_Heart-2016-Blann-975-83.pdf |
| Alternate Webpage(s) | https://doi.org/10.1136/heartjnl-2014-307019 |
| Journal | Heart |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
